RESEARKA

This synthesis addresses the cross-domain tensions in PCSK9 inhibitors longevity evidence by separating mechanistic plausibility from clinical outcome data and weighting evidence according to outcome class and study design. The curated corpus of 51 reference papers reveals a pattern of positive signals in mortality-survival and contextual outcomes coexisting with predominantly null or mixed findings in safety-comorbidity and cardiometabolic domains. Structured evidence mapping identifies cross-study disagreements across outcome classes, with disagreement severity ranging from mild (severity 1) to substantial (severity 4) on key questions such as cognitive safety and vascular aging biomarkers. Our approach explicitly addresses the Ioannidis 2005 concern that surrogate endpoint associations may not guarantee hard-outcome validity by requiring triangulation across mechanistic, biomarker, and clinical-event evidence streams. By distinguishing between what PCSK9 inhibitors demonstrably achieve—potent LDL-C reduction and cardiovascular event prevention—and what remains speculative regarding lifespan extension, this synthesis offers a structured framework for evaluating the PCSK9 inhibitors longevity hypothesis. The clinical vs mechanistic separation we employ is intended to clarify where the evidence supports action and where it merely supports further investigation.

Citation Support

• source_1 Ma 2025
• source_2 Schwartz 2021
• source_3 Lehrke 2024
• source_4 Imran 2023
• source_5 Faraidy 2023